← All Gain Therapeutics, INC filings

Gain Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
GANX
Gain Therapeutics, INC
10-K: Gain Therapeutics Faces Going Concern Doubt Amidst Parkinson's Trial Progress
Gain Therapeutics reports positive Phase 1b Parkinson's trial data for GT-02287 but acknowledges substantial doubt about its ability to continue as a going concern beyond Q1 2027.
NASDAQ
GANX
Gain Therapeutics, INC
10-K: Gain Therapeutics Reports 2024 Financial Results and Provides Business Update
Gain Therapeutics' 10-K filing reveals ongoing efforts in Parkinson's disease treatment development and financial strategies to maintain operations.
NASDAQ
GANX
Gain Therapeutics, INC
10-K: Gain Therapeutics 10-K Filing: Details on Stock, Operations, and Future Plans
Gain Therapeutics' 10-K filing outlines the company's stock structure, ongoing clinical trials, and future strategic directions, while also highlighting financial risks and regulatory challenges.